Targeting mitochondrial dysfunction in neurodegenerative disease: Part I.
about
Mitochondrial dysfunction associated with glucocerebrosidase deficiencyHigh throughput microplate respiratory measurements using minimal quantities of isolated mitochondriaThe efficacy and safety of coenzyme Q10 in Parkinson's disease: a meta-analysis of randomized controlled trials.Cancer and neurodegeneration: between the devil and the deep blue sea.Dopamine induced neurodegeneration in a PINK1 model of Parkinson's disease.Phosphorylation of HtrA2 by cyclin-dependent kinase-5 is important for mitochondrial function.Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration.Mitophagy and Parkinson's disease: the PINK1-parkin link.Targeting mitochondrial dysfunction in neurodegenerative disease: Part II.Modeling mitochondrial encephalomyopathy in Drosophila.Mitochondria, calcium-dependent neuronal death and neurodegenerative disease.Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic.Photo-Induced Oxidative Stress Impairs Mitochondrial Metabolism in Neurons and Astrocytes.Evaluation of the Protective Effects of Sarains on H2O2-Induced Mitochondrial Dysfunction and Oxidative Stress in SH-SY5Y Neuroblastoma Cells.Amyloid β-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition.Mitochondrial Dysfunction in Parkinson's Disease.p62-Keap1-NRF2-ARE Pathway: A Contentious Player for Selective Targeting of Autophagy, Oxidative Stress and Mitochondrial Dysfunction in Prion Diseases
P2860
Q28115678-FB5AF3C2-7E93-4CDC-8EC2-F2B9BAF6C62EQ28479257-278025B9-90A8-4534-8940-57C8BFC90A26Q30395090-6C9BAF61-24A8-4544-96A5-1EF4190A78F3Q33784620-614B6279-325D-4BF7-8813-5EA5105ED605Q34291082-9EC40C71-739D-43B4-BC94-9331145599A1Q35315489-DBE75128-B314-4819-BDCA-22808120BEB0Q37096592-7110A0AF-20F8-4E5C-9C6E-7F909E715DB7Q37587126-85FAEDBE-F780-428E-9B09-0601027B8712Q37718248-DB6B351D-E709-4439-B90C-E8E1AA136136Q37753231-D99CCFF6-5159-4825-956B-F2D7B2186A87Q38012067-0AF959AB-7B1E-44A8-843F-CBD6174C3447Q38196398-DB0C5BBE-DDC2-43D2-BF97-685CC04E367BQ46316459-E831AA20-4952-4F11-B8CC-014CF6CB3EB3Q46370532-FDE91B6D-A126-4F68-B4A4-95A276DF62B7Q49843059-04A4E738-95B7-4662-8D5E-F3F5C9CA411EQ53453128-56D757B1-179F-41F8-B586-B1C959E6F673Q58583990-FE866A16-439B-4EFF-85B8-C215CF031221
P2860
Targeting mitochondrial dysfunction in neurodegenerative disease: Part I.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting mitochondrial dysfunction in neurodegenerative disease: Part I.
@en
Targeting mitochondrial dysfunction in neurodegenerative disease: Part I.
@nl
type
label
Targeting mitochondrial dysfunction in neurodegenerative disease: Part I.
@en
Targeting mitochondrial dysfunction in neurodegenerative disease: Part I.
@nl
prefLabel
Targeting mitochondrial dysfunction in neurodegenerative disease: Part I.
@en
Targeting mitochondrial dysfunction in neurodegenerative disease: Part I.
@nl
P2093
P2860
P1476
Targeting mitochondrial dysfunction in neurodegenerative disease: Part I
@en
P2093
Hélène Plun-Favreau
Sonia Gandhi
Victoria S Burchell
P2860
P304
P356
10.1517/14728221003652489
P407
P577
2010-04-01T00:00:00Z